About: http://webisa.webdatacommons.org/32795883

Property	Value
http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://www.w3.org/ns/prov#Entity
http://www.w3.org/ns/prov#value	cause them to stop receiving it and the protocol remains open....Further Study InformationBACKGROUND:This is a phase II study to determine the activity of bevacizumab, a putative antiangiogenic agent, in Kaposi's sarcoma (KS).
http://www.w3.org/ns/prov#wasQuotedFrom	cancer.gov